|
|
This article needs to be updated. Please update this article to reflect recent events or newly available information. (January 2014) |
Amdoxovir
 |
| Clinical data |
| ATC code |
none |
| Identifiers |
- [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
|
| CAS Number |
145514-04-1  Y |
| PubChem (CID) |
124088 |
| ChemSpider |
110576 Y |
| UNII |
54I81H0M9C Y |
| KEGG |
D02890 Y |
| ChEMBL |
CHEMBL458876 Y |
| NIAID ChemDB |
005431 |
| Chemical and physical data |
| Formula |
C9H12N6O3 |
| Molar mass |
252.23 g/mol |
| 3D model (Jmol) |
Interactive image |
-
n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N
|
-
InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 Y
-
Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N Y
|
| (verify) |
Amdoxovir is a nucleoside reverse transcriptase inhibitor (NRTI) undergoing research for the treatment of HIV/AIDS. It was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia). It is being developed by RFS Pharma.[1] Currently, it is in Phase II clinical studies.
References[edit]
- ^ "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on March 21, 2008. Retrieved March 21, 2008.
External links[edit]
- Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther. 15 (2): 185–192. doi:10.3851/IMP1514. PMID 20386073.
